What We're Reading: Page 265
Industry reads hand-picked by our editors
Sep 17, 2018
-
The Wall Street Journal
The Worst Is Over for Generic-Drug Stocks
-
The New York Times
For elderly women with breast cancer, surgery may not be the best option
-
Associated Press
Few safeguards for foster kids on psych drugs
Sep 14, 2018
-
The New York Times
Top Sloan Kettering Cancer Doctor Resigns After Failing to Disclose Industry Ties
-
Albany Times Union
Regeneron plans to add 1,500 in East Greenbush
-
Reuters
Roche steps up efficiency drive to take sting out of biosimilars
-
Kaiser Health News
Unwitting Patients, Copycat Comments Play Hidden Role In Federal Rule-Making
Sep 13, 2018
Sep 12, 2018
Sep 11, 2018
-
STAT
Amgen emerges as a multiple myeloma drug player, threatening Bluebird, Celgene
-
The New York Times
How teeth became tusks, and tusks became liabilities
-
Scientific American
RNA expert wins "American Nobel"
Sep 10, 2018
-
The Times
Japan's Takeda family brands Shire deal ‘a disaster’
-
Financial Times
Billionaire Sackler family owns second opioid drugmaker
-
The New York Times
Top cancer researcher fails to disclose corporate financial ties in major research journals
-
The Wall Street Journal
Marijuana-research applications go nowhere at Justice Department
Sep 07, 2018
-
Financial Times
Opioid billionaire granted patent for addiction treatment
-
TechCrunch
23andMe underscores that privacy-loving customers need to opt out of its data deal with GlaxoSmithKline
-
Forbes
Will Trump's pharma shaming bring down drug prices? Not likely, poll says
-
Boston Business Journal
Biotech VCs debate AI, globalization during Boston panel
Previous
